Zenas BioPharma (ZBIO) Corporate Presentation summary

Executive leadership and experience

• Leadership team has deep expertise in biopharma, with 70+ INDs, 30+ BLA/NDA filings, and 30+ commercial launches.

• Team members have backgrounds at major pharma and biotech firms, supporting strong development and commercialization capabilities.

Strategic vision and pipeline overview

• Aims to become a global, fully integrated, commercial-stage biopharma company with multi-franchise potential.

• Portfolio includes two late-stage programs (obexelimab, orelabrutinib) and two early-stage programs (ZB021, ZB022) targeting autoimmune and neuroinflammatory diseases.

• By 2031, targets approval of three franchise molecules across five indications in rheumatology, multiple sclerosis, and dermatology.

Obexelimab: clinical progress and commercial potential

• Obexelimab is a bifunctional mAb targeting CD19 and FcyRllb, designed for broad B cell inhibition without depletion.

• Phase 2 IgG4-RD trial showed rapid, sustained disease activity reduction and high remission rates; Phase 3 INDIGO trial topline results expected year-end 2025.

• Market research suggests obexelimab could capture over 45% of the biologics segment for IgG4-RD, with a $1B+ U.S. revenue opportunity.